WG Consulting is the UK Partner for the Prix Galien, an internationally recognised award for innovative medicines.

The UK Prix Galien was established to recognise the pharmaceutical industry's outstanding achievement in the evolution of medicines. WG Consulting acquired the UK franchise in 2004, having successfully managed the award for the previous seven years. The Prix Galien is very much aligned with WG's commitment to excellence and innovation.

A new medicine takes an average of 10 years and more than £200 million to research. Only one or two of over 10,000 compounds evaluated will be granted a licence of use. Of these, only one product in seven goes on to become a commercial success. The Prix Galien recognises these successes. Pharmaceutical companies can enter any new product that they consider innovative and representative of their best research and clinical expertise.

Prix Galien is named after the ancient Roman philosopher and teacher Claudius Galenus (AD 131-201), generally acknowledged as the 'father of modern pharmacology'.

Founded in France in 1969, it has now been adopted in most of Europe, USA and Canada. The winners from each country are put forward for the International Prix Galien which is awarded every two years.